Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-05-14

Schrödinger, Inc.

Schrödinger sells molecular simulation and discovery workflow software to life sciences and materials customers and also monetizes its platform through collaborations and proprietary drug programs.

ai biotech cloud healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow proof can unlock durable upside

The upside case is that hosted delivery and agentic tooling turn a respected modeling suite into a harder-to-replace discovery workflow layer. That could more than double revenue and lift the valuation, but only if pricing and renewals prove the platform is becoming more central, not more commoditized.

Analysis

Thesis

The five-year upside is a workflow-quality upgrade, not a heroic biotech bet: if hosted delivery, LiveDesign embedment, and Bunsen turn Schrödinger from a respected modeling toolkit into a governed discovery operating layer, revenue can more than double and the stock can rerate toward specialized scientific software with biotech option value attached.

Last Economy Alignment

Cheaper cognition and more compute should increase discovery throughput, and Schrödinger owns a real workflow and validation layer. The score stops short of top-tier because generic agents and cheaper modeling tools could still bypass the UI and pressure pricing if LiveDesign does not become the trusted system of record.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.7x (from 5 most recent analyses)

Reasoning

The rerating case is mix quality, not speculative therapeutics. If hosted contracts improve renewal visibility, Bunsen expands usage inside LiveDesign rather than as a stand-alone novelty, and collaboration wins keep validating the science, investors can value the business more like durable scientific workflow software with biotech option value. That supports a solid rerating from a transition-disrupted base, but not a frontier-AI premium.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The key risk is strategic rather than financial. Liquidity is currently adequate; the real question is whether hosted delivery and Bunsen make Schrödinger the governed workflow layer for discovery or merely a better-delivered modeling engine. If agents sit above the stack, pricing compresses, or Q4 renewals fail to prove durable expansion, the company can still grow, but the rerating case weakens sharply.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Q1 2026 results on May 5 showed 12% ACV growth and maintained full-year guidance, which supports underlying demand even as recognized software revenue is distorted by hosted migration.
Management reaffirmed summer 2026 timing for the early-access Bunsen rollout, so the next product proof gate remains live rather than slipping.
The May 5 update highlighted Lilly's announced $2.3 billion acquisition of Ajax, which strengthens the external validation value of Schrödinger's collaboration and co-founder model.
The May conference schedule creates new near-term messaging windows, but no verified new commercial proof beyond the May 5 release has surfaced yet.

Thesis update

No fundamental change. The core case is still that a hosted workflow transition can raise durability and value capture; what improved slightly is evidence that customer demand is holding during the accounting reset.

Forecast update

Cleaner ACV proof, solid liquidity, and sharper collaboration validation justify a modestly stronger rerating assumption, but the ceiling still depends on workflow attachment and renewals.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.60

They control a real molecular-design workflow and validation layer, so cheaper AI can increase the amount of discovery work done through their system. The risk is that generic agents sit on top of the stack and turn them into a back-end engine unless hosted workflows become the trusted place where teams run, verify, and govern the work.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.13

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research